MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Shein Shares Slide 9% in Hong Kong IPO Debut 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Add as a preferred source on Google
WATERTOWN, Mass., March 20, 2018 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 17th Annual Needham Healthcare Conference on Tuesday, March 27 at 11:00 a.m. Eastern Time at the Westin New York Grand Central Hotel in New York City.
Live audio webcasts of the presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multi-drug resistant pathogens highlighted as urgent public health threats by the Centers for Disease Control and Prevention. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed phase 3 clinical trials and is under review for potential approval in complicated intra-abdominal infections by the United States Food and Drug Administration and the European Medicines Agency, and TP-271 and TP-6076, which are in phase 1 clinical trials. Eravacycline is an investigational product only and has not been approved for commercialization. Please visit www.tphase.com for more company information.
Investor Contact:
Argot Partners
Maeve Conneighton
206.899.4940
[email protected]
Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
[email protected]
